RxDoctor Payments DataLook up a doctor →

Tony Tran, MD

Gastroenterology · Oklahoma City, OKNPI 1487829362

Payments from drug & device makers

$10,744in general payments, 2019–2025

Across 682 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$993
  • Gilead$808
  • Sanofi$454
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$10,55998%
  • Education$1852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,744 in reported general payments places this provider in the 70th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$155,233
Medicare patients
656
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$69,450
LinzessLinaclotide33$27,721
TrulancePlecanatide20$15,235
Dexlansoprazole DrDexlansoprazole41$8,713
SutabSod Sulf/Pot Chloride/Mag Sulf49$7,989
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates80$5,212
Colestipol Hcl19$3,656
Mesalamine13$2,802
Pantoprazole Sodium116$2,780
ClenpiqSod Picosulf/Mag Ox/Citric Ac15$2,576
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl146$2,117
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl121$1,935
Esomeprazole Magnesium27$1,847
Omeprazole79$1,565
Sucralfate28$1,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,070$97,17152 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$993$15,23520 claims
Braintree Laboratories, Inc.Sutab$79$7,98949 claims
Ferring Pharmaceuticals Inc.Clenpiq$105$2,57615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 gastroenterology providers in Oklahoma.

Other gastroenterology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →